EUnetHTA Joint Action 3 (2016-20) JA3-WP4
2017 - Web Page

Please click on the link(s) below to access the published assessment(s). When there is no link available, the assessment is still ongoing.

Project IDTitle1st AuthorsCo-AuthorsDedicated Reviewers
Other Technologies
OTCA01Wearable cardioverter-defibrillator (WCD) therapy
in primary and secondary prevention of sudden cardiac arrest in patients at risk
LBI-HTAAAZIQWiG, Avalia-t
OTCA02Antibacterial-coated sutures versus non-antibacterial-coated sutures for the prevention of abdominal, superficial and deep, surgical site infection (SSI)AAZNSPHMPDBSUKL, NIPN/OGYEI,
VASPVT, SNHTA, IQWiG
OTCA03Screening of fetal aneuploidies whereby non-invasive prenatal test (NIPT)Avalia-tRERMIDT, SNHTA, NIPN
Observer: EOPYY
OTCA04Added value of using gene-expression signature for adjuvant chemotherapy decisions in early breast cancerZINKCELBI-HTA, HAS
OTCA05Repetitive transcranial magnetic stimulation for treatment-resistant major depressionLBI-HTAOstebaKCE, FUNCANIS
Pharmaceutical technologies
PTJA01Midostaurin for the indication of Acute Myeloid LeukaemiaFIMEANOMATLV, ZIN, HAS, NICE, AEMPS, IQWIG

Observer: SUKL, SU, EOPPY, SESCS
PTJA02Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib treatmentHASINFARMEDAAZ, SNHTA, FIMEA, LBI, NIPN, AETSA

Observer: EOF, EKAPTY

Abbreviations: OT-other technologies, PT-pharmaceutical technologies, CA-collaborative assessment, JA-joint assessment